EcoR1 Capital, LLC

Track record

How each disclosed position did against the S&P ~6 months later

The outcome curve and every position's resultPro →

+26.8%

median move per position

+7.6%

S&P 500 median, same spans

1 of 1

beat the S&P ~6mo later

Disclosed positions

Estimated from their latest filings — positions may have changed since

Estimated positions from their latest filingsPro →

Activity

Open-market buy & sell volume

BuySell

Total +$40.00M bought · −$6.89M sold

All filings on record

Every Form 4 transaction we track for this filer

All10Buys2Sells3

Stock	Transaction	Date	~6mo vs S&P
AKTSAktis Oncology, Inc.	Buy $2.60M · 144,443 sh	2026-01-12	—
AKTSAktis Oncology, Inc.	Buy $37.40M · 2,077,779 sh	2026-01-12	—
AKTSAktis Oncology, Inc.	Convert — · 128,506 sh	2026-01-12	—
AKTSAktis Oncology, Inc.	Convert — · 202,862 sh	2026-01-12	—
AKTSAktis Oncology, Inc.	Convert — · 2,270,879 sh	2026-01-12	—
ADAPAdaptimmune Therapeutics PLC	Sell $2.80M · 27,433,338 sh	2025-07-30	—
ADAPAdaptimmune Therapeutics PLC	Sell $272.0K · 2,687,460 sh	2025-07-29	—
ADAPAdaptimmune Therapeutics PLC	Sell $3.82M · 33,931,740 sh	2025-07-28	—
ZYMEZymeworks Inc.	Tax $521.11 · 41 sh	2025-06-26	—
ZYMEZymeworks Inc.	Other $508.65 · 5,086,480 sh	2025-06-26	—

AKTSBuy

2026-01-12 · Aktis Oncology, Inc.

$2.60M

—

AKTSBuy

2026-01-12 · Aktis Oncology, Inc.

$37.40M

—

AKTSConvert

2026-01-12 · Aktis Oncology, Inc.

128,506

—

AKTSConvert

2026-01-12 · Aktis Oncology, Inc.

202,862

—

AKTSConvert

2026-01-12 · Aktis Oncology, Inc.

2,270,879

—

ADAPSell

2025-07-30 · Adaptimmune Therapeutics PLC

$2.80M

—

ADAPSell

2025-07-29 · Adaptimmune Therapeutics PLC

$272.0K

—

ADAPSell

2025-07-28 · Adaptimmune Therapeutics PLC

$3.82M

—

ZYMETax

2025-06-26 · Zymeworks Inc.

$521.11

—

ZYMEOther

2025-06-26 · Zymeworks Inc.

$508.65

—

10 filings·Every Form 4 on record, with outcomesPro →

Filing in the same companies

Other insiders active in these names in the last 3 years

CA

Czibere Akos

AKTS · last 2026-07-08

RB

Ron-Bigger Shulamit

AKTS · last 2026-07-08

HM

Hollywood Mark

ZYME · last 2026-07-06

FT

Foley Todd

AKTS · last 2026-01-12

GA

Gadicke Ansbert

AKTS · last 2026-01-12

GK

Galbraith Kenneth

ZYME · last 2026-01-12

Outcomes measure each position — the first buy in a stock and every buy within 182 days — against the closing price ~6 months (120 trading days) later, with the S&P 500 over the same span for context. Pre-scheduled 10b5-1 plan trades are excluded from the record. Positions are estimated from the latest reported post-transaction holdings, split-adjusted, at the latest close. Built from SEC Form 4 filings and market prices — past outcomes, not predictions or advice.